Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02569892
Recruitment Status : Active, not recruiting
First Posted : October 7, 2015
Last Update Posted : March 18, 2020
Sponsor:
Collaborator:
Bascom Palmer Eye Institute
Information provided by (Responsible Party):
Steven R. Sanislo, Stanford University

Brief Summary:
This is a randomized controlled study of non-damaging photothermal macular grid laser versus sham laser therapy in patients with dry age-related macular degeneration (AMD) and large high-risk drusen. The goal of the study is to determine if this treatment will reduce macular drusen volume and also whether this might improve visual acuity or reduce the risk of conversion to advanced age-related macular degeneration defined as development of choroidal neovascularization or geographic atrophy.

Condition or disease Intervention/treatment Phase
Macular Degeneration Retinal Drusen Device: macular laser treatment Device: sham macular laser treatment Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration
Actual Study Start Date : September 1, 2016
Actual Primary Completion Date : February 1, 2020
Estimated Study Completion Date : May 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Laser Arm
Sub-threshold laser utilizing Pascal laser with endpoint-management software
Device: macular laser treatment
Sub-threshold macular laser treatment with Pascal laser Endpoint Management System

Sham Comparator: Sham Laser Arm
Sham laser treatment
Device: sham macular laser treatment
Sham macular laser treatment with Pascal laser power setting of zero




Primary Outcome Measures :
  1. Change in macular drusen volume [ Time Frame: 12 and 24 months ]
    Mean change in macular drusen volume as measured on high-resolution spectral domain ocular coherence tomography (SD-OCT)


Secondary Outcome Measures :
  1. Change in visual acuity [ Time Frame: 12 and 24 months ]
    Mean change in best-corrected visual acuity as measured using early treatment diabetic retinopathy study (ETDRS) chart

  2. Development of geographic atrophy (GA) or choroidal neovascularization (CNV) [ Time Frame: 2 years ]
    Percentage of subjects who develop geographic atrophy or choroidal neovascularization by 24 months.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Older than 60 years of age.
  2. Male or female patients with nonexudative AMD with a drusen volume of of at least 0.03mm3 in the central 3mm circle
  3. Adequate pupil dilatation and clear media to perform colour, red-free imaging and fundus fluorescein angiography, fundus autofluorescence imaging and OCT.
  4. Able to give an informed consent.

Exclusion Criteria:

  1. Presence of signs of advanced AMD, such as CNV, haemorrhages or macular atrophy based on OCT and fundus autofluorescence photography (FAF).
  2. Previous macular laser treatment.
  3. Any previous ocular condition that may be associated with a risk of developing macular oedema.
  4. Vitreomacular traction determined clinically and /or by OCT, which in the opinion of the investigator, contributes to the macular oedema (associated or causing a detachment of the fovea).
  5. Presence of other macular disease such as epiretinal membrane, macular telangiectasia.
  6. Important known allergies to sodium fluorescein dye used in angiography.
  7. Ocular or periocular infections.
  8. Planned intra-ocular surgery within one year.
  9. Patient is unavailable for follow-up visits.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02569892


Locations
Layout table for location information
United States, California
Byers Eye Institute at Stanford University
Palo Alto, California, United States, 94303
Sponsors and Collaborators
Stanford University
Bascom Palmer Eye Institute
Investigators
Layout table for investigator information
Principal Investigator: Steven Sanislo, MD Stanford University
Layout table for additonal information
Responsible Party: Steven R. Sanislo, Professor, Stanford University
ClinicalTrials.gov Identifier: NCT02569892    
Other Study ID Numbers: IRB-33991
First Posted: October 7, 2015    Key Record Dates
Last Update Posted: March 18, 2020
Last Verified: March 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Drusen
Retinal Degeneration
Retinal Diseases
Eye Diseases